Govt to offer incentives to support 75 start-ups in Tele-Medicine, AI and Digital Health
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Subscribe To Our Newsletter & Stay Updated